DreamCIS (A223250) Stock Overview
Operates as a clinical research organization in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
A223250 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
DreamCIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,750.00 |
| 52 Week High | ₩8,070.00 |
| 52 Week Low | ₩2,435.00 |
| Beta | 0.37 |
| 1 Month Change | -9.16% |
| 3 Month Change | 29.94% |
| 1 Year Change | 104.63% |
| 3 Year Change | 89.77% |
| 5 Year Change | 30.68% |
| Change since IPO | -24.59% |
Recent News & Updates
Recent updates
DreamCIS, Inc. (KOSDAQ:223250) Held Back By Insufficient Growth Even After Shares Climb 56%
Dec 18
Calculating The Intrinsic Value Of DreamCIS, Inc. (KOSDAQ:223250)
Nov 27DreamCIS, Inc. (KOSDAQ:223250) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Oct 28Getting In Cheap On DreamCIS, Inc. (KOSDAQ:223250) Is Unlikely
Sep 04DreamCIS' (KOSDAQ:223250) Performance Is Even Better Than Its Earnings Suggest
May 24A Look At The Fair Value Of DreamCIS, Inc. (KOSDAQ:223250)
Dec 17DreamCIS, Inc.'s (KOSDAQ:223250) Shares Climb 29% But Its Business Is Yet to Catch Up
Oct 21DreamCIS, Inc.'s (KOSDAQ:223250) 29% Price Boost Is Out Of Tune With Earnings
Jul 11DreamCIS, Inc.'s (KOSDAQ:223250) Share Price Not Quite Adding Up
Apr 26We Think You Should Be Aware Of Some Concerning Factors In DreamCIS' (KOSDAQ:223250) Earnings
Mar 20Estimating The Intrinsic Value Of DreamCIS, Inc. (KOSDAQ:223250)
Mar 19Shareholder Returns
| A223250 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -8.7% | -0.1% | 5.9% |
| 1Y | 104.6% | 15.3% | 101.6% |
Return vs Industry: A223250 exceeded the KR Life Sciences industry which returned 15.3% over the past year.
Return vs Market: A223250 exceeded the KR Market which returned 101.6% over the past year.
Price Volatility
| A223250 volatility | |
|---|---|
| A223250 Average Weekly Movement | 12.9% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A223250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A223250's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 390 | n/a | www.dreamcis.com |
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea.
DreamCIS, Inc. Fundamentals Summary
| A223250 fundamental statistics | |
|---|---|
| Market cap | ₩136.85b |
| Earnings (TTM) | ₩18.58b |
| Revenue (TTM) | ₩62.06b |
Is A223250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A223250 income statement (TTM) | |
|---|---|
| Revenue | ₩62.06b |
| Cost of Revenue | ₩40.92b |
| Gross Profit | ₩21.15b |
| Other Expenses | ₩2.57b |
| Earnings | ₩18.58b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 780.63 |
| Gross Margin | 34.07% |
| Net Profit Margin | 29.93% |
| Debt/Equity Ratio | 11.2% |
How did A223250 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 22:57 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DreamCIS, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyun Dong Lee | NH Investment & Securities Co., Ltd. |
| Seunghwan Choi | Shinhan Investment Corp. |